Exhibit 32.1
CERTIFICATION PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)
In connection with the accompanying Quarterly Report of Ultragenyx Pharmaceutical Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2024 (the “Report”), I, Emil D. Kakkis, M.D., Ph.D., as President and Chief Executive Officer of the Company, and Howard Horn, as Executive Vice President and Chief Financial Officer, Corporate Strategy of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
Dated: August 1, 2024 | /s/ Emil D. Kakkis | |
Emil D. Kakkis, M.D., Ph.D. | ||
President and Chief Executive Officer |
Dated: August 1, 2024 | /s/ Howard Horn | |
Howard Horn | ||
Executive Vice President, Chief Financial Officer, Corporate Strategy (Principal Financial Officer) |